CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Celera Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Celera Corporation
1401
Harbor Bay Parkway
Phone: (510) 749-4200p:510 749-4200 Alameda, CA  94502-7070  United States Ticker: CRACRA

This company was Merged or Acquired on 5/3/2011.
This company ceased filing statements with the SEC on 6/2/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Celera Corporation (Celera) is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services. It has three reporting segments: Lab Services, which includes a clinical laboratory testing service business, Products, which includes a business in products, and Corporate, which includes other activities under corporate management. Lab Services business, conducted through Berkeley HeartLab, Inc. (BHL), offers a portfolio of clinical laboratory tests and disease management services designed to help physicians improve cardiovascular disease treatment regimens for their patients. Products business develops, manufactures, and oversees the commercialization of molecular diagnostic products. In May 2011, Celera was acquired by Quest Diagnostics Incorporated.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/26/201112/25/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board William G.Green 66 8/1/2008 7/1/2008
Chief Executive Officer, Director Kathy P.Ordonez 60 2/1/2008 8/15/2002
Chief Financial Officer, Senior Vice President Alfred G.Merriweather 57 12/20/2010 12/20/2010
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Axys 468 Littlefield LLC
Axys Pharmaceuticals, Inc.
Berkeley HeartLab, Inc.
8 additional Business Names available in full report.

General Information
Number of Employees: 490 (As of 12/25/2010)
Outstanding Shares: 82,181,869 (As of 4/22/2011)
Shareholders: 4,316
Stock Exchange: NASD
Federal Tax Id: 262028576
Email Address: webmaster@celera.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023